Drugs / Exenatide extended-release
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02119819 | Apr 2014 → Aug 2015 | type 2 diabetes mellitus | OPKO Health, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02787551 Comparator | Jul 2016 → May 2018 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | exenatide extended-release | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02787551 ↗ |
| Action | Activate | “GLP-1 RA receptor agonist” NCT02787551 ↗ |
| Route | Subcutaneous | “Administered SC” NCT02119819 ↗ |